Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.47 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5575428 | 1.00 | MEN1 (0.49) | MEN1KMT2AGPR119USP30TP53 | |
| SCHEMBL4597776 | 0.89 | TP53 (0.47) | MEN1KMT2AGPR119USP30TP53 | |
| SCHEMBL4596720 | 0.85 | RAB9A (0.44) | MEN1KMT2AKDM4EMAPT | |
| SCHEMBL5575231 | 0.83 | GPR119 (0.53) | GPR119USP30POLBKDM4EMAPT | |
| SCHEMBL4624953 | 0.83 | GPR119 (0.53) | GPR119USP30POLBKDM4EMAPT | |
| SCHEMBL4596495 | 0.83 | GPR119 (0.49) | MEN1KMT2AGPR119USP30KDM4E | |
| SCHEMBL4596490 | 0.83 | GPR119 (0.49) | MEN1KMT2AGPR119USP30KDM4E | |
| SCHEMBL5573931 | 0.82 | GPR119 (0.48) | MEN1KMT2AGPR119USP30KDM4E | |
| SCHEMBL4597967 | 0.82 | GPR119 (0.48) | MEN1KMT2AGPR119USP30KDM4E | |
| SCHEMBL4596612 | 0.82 | GPR119 (0.58) | GPR119USP30KDM4EMAPTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070066624-A1 | Chemokine receptor binding compounds | ANORMED, INC. (CA) | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066624-A1 | Chemokine receptor binding compounds | CCR5, CCR4, CCR1 | MEN1 4855/4885KMT2A 4627/4885GPR119 229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.